Roth Capital analyst, Joeseph Pantginis, reiterated his Buy rating on Lion Biotechnologies (NASDAQ: LBIO) after the announcement yesterday evening that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE